SCHEMBL24427509

SCHEMBL24427509

Cc1nc(F)c(-c2ccc3[nH]ncc3c2F)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 3/20 0.50
▸ CDK2 P24941 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ CCNA1 P78396 1/20 0.35
▸ ESR1 P03372 6/20 0.34
▸ ESR2 Q92731 5/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ DRD1 P21728 1/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ TGFBR2 P37173 1/20 0.33
▸ METAP2 P50579 3/20 0.33
▸ AXL P30530 1/20 0.33
▸ PIK3CD O00329 1/20 0.32
▸ PIK3CA P42336 1/20 0.32
▸ PIK3CB P42338 1/20 0.32
▸ PIK3CG P48736 1/20 0.32
▸ HAVCR2 Q8TDQ0 1/20 0.32
▸ HASPIN Q8TF76 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24427503 0.86 TRPA1 (0.51) TRPA1CDK2FLT3CCNA1ESR1
SCHEMBL24428002 0.75 TRPA1 (0.48) TRPA1ESR1ESR2IDO1DRD1
SCHEMBL30494470 0.72 TRPA1 (0.51) TRPA1METAP2PIK3CA
SCHEMBL24427504 0.72 TRPA1 (0.51) TRPA1TGFBR1TGFBR2
SCHEMBL26463445 0.72 TRPA1 (0.51) TRPA1METAP2PIK3CA
SCHEMBL29769117 0.71 TRPA1 (0.47) TRPA1CDK2FLT3CCNA1ESR1
SCHEMBL9909086 0.71 TRPA1 (0.47) TRPA1CDK2FLT3CCNA1ESR1
SCHEMBL24427783 0.71 KDM4E (0.35) —
SCHEMBL12438648 0.68 IDO1 (0.41) TRPA1CDK2CCNA1IDO1METAP2
SCHEMBL24427865 0.68 KDM4E (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) 2022-12-06 — — US disclosed
EP-3998263-A1 TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2022-05-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11518766-B2 Tricyclic compound, preparation method therefor and use thereof TFPI, TFPI2, F11 TRPA1 1687/4885CDK2 2408/4885FLT3 1492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback